Critical design considerations for time-to-event endpoints in amyotrophic lateral sclerosis clinical trials

Abstract

BackgroundFunding and resources for low prevalent neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS) are limited, and optimising their use is vital for efficient drug development. In this study, we...